The 11th floor of the Robert W. Franz Cancer Center is home to the Providence Cancer Institute Franz Clinic, offering expanded services for personalized cancer care. See how we're working to finish cancer. Learn more ›

Providence Cancer Institute-Oregon

Latest news

T-cell checkpoint antibodies have revolutionized immunotherapy for cancer, including renal cancer. At Providence Cancer Institute, several clinical trials of these novel approaches are now open to patients with renal cell...

A new phase 3 study open at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, will evaluate the curative potential of adjuvant pembrolizumab in patients...

In a matter of minutes William Kennedy went from explaining how unfortunate he is – with his diagnosis of incurable cancer – to how fortunate he is – finding Providence and hope. He told the attendees at...

In the last year, the combination of pembrolizumab (Keytruda) with chemotherapy has become a frontline treatment for people with metastatic non-small cell lung cancer (NSCLC). The FDA granted full approval for the...

A newly opened study for metastatic HER2-negative breast cancer will evaluate an alternative systemic treatment combination that omits or delays the use of chemotherapy while improving the efficacy and durability of...

Identical twin astronauts – one grounded on Earth and the other launched into space – proved to be fascinating research subjects for Providence genomics expert and cancer researcher Brian Piening, Ph.D., who...

The light-activated drug ASP-1929 is showing promise as a potential new treatment for people with recurrent head and neck cancers. A new study of this first-in-class, precision targeted therapy is opening soon at...

Phase 1 studies are the springboard for advancing new cancer treatments. Through phase 1 studies, the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is...

Emerging research is finding that immunotherapy may extend survival for some women with triple-negative breast cancer. Providence Cancer Institute, a leader in immunotherapy research, is actively investigating options for...

Checkpoint inhibitors are showing promise as a potential new line of treatment for people with liver cancer. The Earle A. Chiles Research Institute at Providence Cancer Institute currently has six studies open to liver...

Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new clinical trial at Providence Cancer Institute.

The 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center is now open and blessed! This new space allows us to expand and consolidate our outpatient cancer services in the new Providence...

From groundbreaking research to innovative treatments to compassionate care, everything we do at Providence Cancer Institute is for you, our patients. That's why we have expanded and consolidated outpatient cancer services...

Recent research has opened up new treatment options for advanced bladder cancer and other urothelial cancers, and clinical trials are contributing to the growing knowledge of how checkpoint inhibitors and other...

More than 161,000 American men will be diagnosed with prostate cancer this year, and nearly 27,000 will die of the disease. While prostate cancer is one of the most common cancers among American men, it also is very...

Phase 1 studies are the springboard for advancing new cancer treatments. The Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is often able to offer...

Researchers at the Earle A. Chiles Research Institute, or EACRI, and Agonox, Inc. have published groundbreaking work concerning tumor-killing T cells which could greatly improve the immune response in cancer patients...

In a powerful speech to a packed house, Becky Roth spoke emotionally about the cancer that changed, but didn’t claim, her life. And, despite losing two leg bones used for her jaw reconstruction – and against...

For people with advanced lung cancer, clinical trials open up new treatment options and offer access to promising new therapies. At Providence Cancer Institute, 19 studies of novel lung cancer therapies are open to...

Women with metastatic hormone-receptor-positive, HER2-negative breast cancer who have progressed after treatment with a CDK4/6 inhibitor may qualify for a newly opened immunotherapy study at Providence Cancer Institute.

A recent assessment of the first 170 throat-cancer patients treated with transoral robotic surgery followed by risk-adapted adjuvant therapy at Providence Cancer Institute offers compelling evidence in favor of this new...

Many clinical trials are open only to patients with metastatic disease. One of the translational research goals of the Providence Head and Neck Cancer Program is to bring immunotherapy into treatment earlier.

Adoptive T-cell transfer therapy is emerging as one of the most effective treatments to date for people with advanced melanoma. Now this treatment is available to patients with advanced or recurrent head and neck cancers...

It was a year in the record books for Providence Foundations of Oregon in 2017. They raised more than $50 million - and received the single largest gift ever - marking the most successful fundraising year in the 35 year...

For people with advanced lung cancer, clinical trials open up new treatment options and offer access to promising new therapies. At Providence Cancer Institute, 20 studies of novel lung cancer therapies are open to...

T-cell checkpoint antibodies have revolutionized immunotherapy for cancer, including renal cancer. At Providence Cancer Institute, several clinical trials of these novel approaches are now open to patients with renal...

Phase I studies are the foundation for advancing cancer treatment with new agents and combinations of therapies. Providence Cancer Institute is often able to offer patients first-in-human clinical trials of novel cancer...

A first-of-its-kind clinical study may offer new hope to patients battling rectal cancer.
The Phase 2 study, newly underway at Providence Cancer Institute, is led by Kristina Young, M.D., Ph.D., who was recognized in 2016...

Patients with hormone-receptor-positive, HER2-positive metastatic breast cancer may qualify for a newly opened clinical trial at Providence Cancer Institute. The PATINA trial expects to demonstrate that adding the...

With the release of her book Patient 71, Australia native Julie Randall has given cancer patients across the globe hope for life after cancer. Her remarkable story of overcoming stage IV metastatic melanoma was featured in...

Known as "Patient 71," persistence paid off for Australian cancer patient Julie Randall
Learn more about her story ›
She now devotes her time to sharing her inspirational story and spreading a word of hope to...

Providence Health & Services in Oregon is a not-for-profit Catholic network of hospitals, care centers, health plans, physicians, clinics, home health care and affiliated services guided by a Mission of caring that the Sisters of Providence began in the West nearly 160 years ago.